Other News To Note
Wednesday, March 30, 2011
Heptares Therapeutics Ltd.of Welwyn Garden City, UK, said it has demonstrated that fragment-based drug discovery methods can be applied to the screening of G protein-coupled receptors (GPCRs) by stabilizing the GPCRs with StaR technology. Results were published in a recent issue of Methods in Enzymology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.